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Abstract The n-3 polyunsaturated fatty acids (PUFA) present primarily in oily fish, namely
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are important
components of cell membranes that are needed for normal development and cell
function. Humans have very limited capacity for EPA and DHA synthesis from a-
linolenic acid and so they must be obtained pre-formed from the diet. However,
perceived unpalatability of oily fish and fish oil concerns about contamination
with environmental pollutants, dietary choices that exclude fish and animal
products, and price limit the effectiveness of recommendations for EPA and DHA
intakes. Moreover, marine sources of EPA and DHA are diminishing in the face
of increasing demands. Therefore, an alternative source of EPA and DHA is
needed that is broadly acceptable, can be upscaled and is sustainable. This review
discusses these challenges and, using findings from recent nutritional trials,
explains how they may be overcome by seed oils from transgenic plants
engineered to produce EPA and DHA. Trials in healthy men and women assessed
the acute uptake and appearance in blood over 8 hours of EPA and DHA from
transgenic Camelina sativa compared to fish oil, and the incorporation of these
PUFA into blood lipids after dietary supplementation. The findings showed that
postprandial EPA and DHA incorporation into blood lipids and accumulation in
plasma lipids after dietary supplementation was as good as that achieved with fish
oil. The oil derived from this transgenic plant was well tolerated. This review also
discusses the implications for human nutrition, marine ecology and agriculture.
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n-3 polyunsaturated fatty acids in tissues
and in the diet
n-3 (also known as omega-3) polyunsaturated fatty
acids (PUFA) are a group of fatty acids in which the
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first double bond is three carbons from the methyl end
of the molecule. In humans, n-3 PUFA in the diet and
in cell membranes typically vary in the length of the
hydrocarbon chain between 18 and 22 carbons, and in
the degree of unsaturation between three and six dou-
ble bonds, all in the cis configuration (Burdge &
Calder 2015). The four principle n-3 PUFA are
unevenly distributed between tissues (Arterburn et al.
2006), which suggests that their incorporation into
cell membranes is related to specific cell functions. a-
Linolenic acid (18:3n-3, ALA) and eicosapentaenoic
acid (20:5n-3, EPA) each account for less than 1% of
total membrane fatty acids in human tissues (Arter-
burn et al. 2006). In contrast, docosahexaenoic acid
(22:6n-3, DHA) accounts for over 20% of fatty acids
in the retina and more than 15% of total sperm and
cerebral cortex fatty acids (Arterburn et al. 2006).
Longer chain, more unsaturated n-3 PUFA also exist
as metabolic intermediates that do not accumulate in
cells, for example, 24:6n-3 in the Sprecher pathway
(Leonard et al. 2004), and in specialised membrane
structures, such as lipid rafts, which contain n-3 PUFA
with chain length ≥24 carbons (Vasireddy et al. 2007).
ALA is the only omega-3 PUFA that is considered
to be essential in the human diet (Baker et al. 2016),
although DHA may be conditionally essential during
pregnancy (Larque et al. 2002). ALA is found in a
number of seeds and seed oils, such as walnut oil, soy-
bean oil and flaxseed oil, in which ALA contributes
approximately 50% of the seed oil fatty acids. Typical
intakes of ALA in European countries, North America
and Australia range from 0.5 to 2.5 g/day (Ollis et al.
1999; Kris-Etherton et al. 2000; Burdge & Calder
2005a). EPA, docosapentaenoic acid n-3 (22:5n-3,
DPAn-3) and DHA are absent from plants; the main
dietary sources of these fatty acids are oily fish, such
as salmon, sardines and mackerel, and their food
products (Monroig et al. 2018) and, albeit in mark-
edly lower amounts, meat and dairy products (Dugan
et al. 2018).
Omega-3 polyunsaturated fatty acids and
human health
There is a robust literature that demonstrates that ade-
quate consumption of n-3 PUFA derived from marine
fish, specifically EPA and DHA, are important for
maintaining health across the life course. For example,
EPA + DHA status (Albert et al. 2002) and dietary
intake (He et al. 2004) have been shown to improve
cardiovascular health and pharmaceutical preparations
of these fatty acids have been demonstrated in meta-
analyses to be as effective as statins in preventing
myocardial infarction (Studer et al. 2005), with incon-
sistencies in outcomes between studies likely to be
attributable to limitations in the study designs (Calder
& Yaqoob 2012). Increased EPA plus DHA intakes
can also improve chronic inflammatory and allergic
diseases such as rheumatoid arthritis (Miles & Calder
2012), asthma and inflammatory bowel disease
(Calder 2015). Such beneficial effects on health are
mediated via changes in the structure and function of
cell membranes (both lipid and protein components)
and by altering the profile of secreted eicosanoids and
specialised pro-resolving lipid mediators (Thies et al.
2003; Calder 2012; Calder 2015). Furthermore, ade-
quate accumulation of DHA into neural membranes is
important for the normal development of the retina
and central nervous system (Carlson & Neuringer
1999; Lauritzen et al. 2001).
In recognition of these positive impacts on health,
several regulatory/advisory bodies have made recom-
mendations for intakes of EPA plus DHA ranging
from 250 to 1000 mg/day in order to promote opti-
mal health. In the UK, the Scientific Advisory Com-
mittee on Nutrition (SACN) recommended that all
adults should consume at least 450 mg/day of EPA
plus DHA (SACN 2004). However, the effectiveness
of such recommendations in promoting health is lim-
ited by dietary choices and the sustainability of the
supply of marine fish as a primary source of these
fatty acids.
Challenges to optimal EPA and DHA
intakes in the UK population
Despite the strength of the evidence in support of the
health benefits derived from regular consumption of
EPA and DHA, habitual intakes of these fatty acids
across the UK population are disappointingly low.
Total fish consumption in the UK has decreased by
approximately 25% since 1950, and only 27% of
adult fish consumers regularly eat oily fish (Givens &
Gibbs 2006). Consequently, most UK adults consume
less than 50% of the amount of EPA plus DHA that
is recommended to maintain health. EPA plus DHA
intake in children is approximately only 10% of that
in adults (Givens & Gibbs 2008). Although cost of
oily fish may be a concern, the perceived unpalatabil-
ity of oily fish also appears to be a major barrier to its
consumption (Givens & Gibbs 2008). Approximately
11% of the UK population regularly consume EPA
plus DHA as a fish oil dietary supplement, which is
most common in individuals aged over 55 years (Food
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Standards Agency 2008). The use of fish oil supple-
ments is also limited by perceived unpalatability, cost
and concerns about contamination with pollutants.
Furthermore, inconsistencies have been identified in
the quality of fish oil supplements (Albert et al. 2015)
although others have not found this to be the case
(Nichols et al. 2016; Bannenberg et al. 2017). Dietary
choices that exclude meat, dairy products and/or fish
induce lower EPA and DHA status (Sanders 2009;
Burdge et al. 2017), which is not offset by metabolic
adaptations during pregnancy (Postle et al. 1995),
such that breastmilk and infant blood EPA and DHA
have been reported to be approximately 50% lower in
vegetarians and vegans, compared to omnivores (San-
ders & Reddy 1992). However, despite the impor-
tance of DHA as a component of neural membranes,
neither vegetarian dietary choice (Crozier et al. 2019)
nor maternal DHA status (Crozier et al. 2018) in
pregnancy appears to affect cognitive function in chil-
dren.
a-Linolenic acid is not an effective
alternative to pre-formed EPA and DHA in
the diet
EPA and DHA can be synthesised by some mammals,
in particular rodents, from ALA (Voss et al. 1991).
This finding has underpinned a number of studies that
have sought to test whether ALA is, through meta-
bolic interconversion, an effective alternative source of
EPA and DHA to consuming these PUFA pre-formed.
If that were the case, this would address at least some
of the major barriers to achieving recommended EPA
and DHA intakes, in particular cost, palatability and
exclusion of animal-derived foods from the diet. How-
ever, the results of dietary intervention trials that
increased ALA intake (Burdge & Calder 2006; Baker
et al. 2016) and of stable isotope tracer studies involv-
ing labelled ALA (Burdge 2004) have shown that the
activity of this pathway is low in humans such that
capacity for EPA synthesis is limited in men and
women (Burdge & Wootton 2002; Burdge et al. 2002)
and there is no evidence of DHA synthesis in men
(Burdge et al. 2002). However, women are able to
synthesise DHA (Burdge & Wootton 2002) and main-
tain higher DHA status than men (Lohner et al. 2013)
irrespective of their background diet (Welch et al.
2010). This sex difference in capacity for DHA syn-
thesis and DHA status appears to be lost in older indi-
viduals (Pittaway et al. 2015) who, therefore, are
likely to have a greater reliance on consuming pre-
formed EPA + DHA than younger people. Thus,
increased intake of ALA does not provide an alterna-
tive dietary source of EPA and DHA to consuming
these PUFA pre-formed (Burdge & Calder 2006).
Moreover, dietary supplementation with stearidonic
acid (18:4n-3, SDA), the product of the initial rate-
limiting reaction in hepatic conversion of ALA to EPA
and DHA, has been shown to increase EPA and
DPAn-3 status, but not that of DHA (James et al.
2003). Increased consumption of SDA, which is only
present in significant amounts in members of the genus
Echium (Guil-Guerrero et al. 2001), is also an unsuit-
able dietary strategy for increasing EPA + DHA levels.
Overall, these findings show that plant-derived n-3
fatty acids, specifically ALA and SDA, are not effective
replacements for pre-formed EPA and DHA in the
human diet (Plourde & Cunnane 2007).
Meeting global demands for EPA and DHA
is a major burden on marine ecology
There is an emerging consensus that a daily intake of
approximately 500 mg EPA + DHA per individual
would confer health benefits, which Salem and Eggers-
dorfer (2015) estimate would require 1.3 million met-
ric tonnes annually of EPA plus DHA for the seven
billion humans that inhabit the Earth. Currently, mar-
ine sources can supply 0.2 million metric tonnes of
EPA plus DHA; about 16% of the required global
provision of EPA plus DHA (Salem & Eggersdorfer
2015). Wild fish capture has remained static since the
1990s, although the production of farmed fish has
increased exponentially during this period. However,
aquaculture also represents a major demand on world
fish oil supply as this is required for rearing of many
farmed species (Tocher 2015). There is also increasing
demand for highly purified EPA and DHA for prepa-
ration of ethyl ester-based pharmaceutical products
which incurs high production losses (90–95%; Kitessa
et al. 2014).
Thus, there is a critical need for novel, sustainable
and scalable sources of EPA and DHA in order to
ensure sufficient supply for the global population.
Crustacea and algal sources of pre-formed EPA and
DHA
Krill oil has been proposed as an alternative to oily
fish as a source of EPA plus DHA. However, the esti-
mated yield from the total krill catch in 2013 was 625
metric tonnes, about 0.3% of the global EPA + DHA
requirement (Kwantas & Grundmann 2015).
Although this could be increased to 9% with
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considerable investment, this would have implications
for the conservation and stability of marine food webs
in the South Atlantic (Kwantas & Grundmann 2015).
Furthermore, claims for greater bioavailability of n-3
PUFA from krill oil compared to fish oil have been
shown to be unfounded (Salem & Kuratko 2014).
Algal oils that contain DHA or EPA plus DHA have
also been proposed as an alternative source of these
fatty acids (Kuratko et al. 2013) and these currently
account for 2% of human EPA + DHA consumption
(Salem & Eggersdorfer 2015). However, the current
costs of fermentation and refining processes are sub-
stantially greater than for fish oil production and
hence algal oils are not likely to be economically com-
petitive in the medium term as a replacement for oily
fish in the human diet (Salem & Eggersdorfer 2015).
Oils from genetically modified plants as a
source of EPA and DHA
Vegetable oils derived from genetically modified plants
represent a potentially attractive alternative source of
EPA and DHA for human consumption since such oils
may overcome the concerns about palatability, sus-
tainability and contamination that are associated with
fish oil, the limited conversion of ALA in humans, and
the cost and conservation issues associated with algal
oils and krill oil, respectively. Importantly, the health
benefits derived from fish oil are due to both EPA and
DHA although their functions may differ (Innes &
Calder 2018), and thus, oils from transgenic plants
that only contain one of these n-3 PUFA may have
limited effectiveness in supporting optimal health com-
pared to consuming both pre-formed EPA and DHA.
There are no native land plant species which can
synthesise EPA and DHA. However, genetic insertion
of desaturase and elongase enzymes from yeast and
algae into plants that naturally produce ALA has facil-
itated the development of strains of canola (oilseed
rape) and Camelina sativa (C. sativa) which produce
oils that contain either EPA or DHA, or EPA plus
DHA in proportions that approximate, to varying
extents the EPA and DHA contents of at least some
fish oils (Fig. 1; Napier et al. 2019; Han et al. 2020).
A transgenic strain of canola that produces an oil con-
taining 10% DHA, but less than 1% EPA has been
developed by the Commonwealth Scientific and Indus-
trial Research Organisation (Petrie et al. 2020) and
commercialised by Nuseed (Tocher et al. 2019). Simi-
larly, a transgenic strain of canola that produces a
seed oil which contains 0.2% DHA and 8.1% EPA
has been commercialised by Cargill for aquaculture
feed (Napier et al. 2019). However, as far as we are
aware, there is no information in the public domain
that reports testing of the oils produced by transgenic
strains of canola for their effectiveness in replacing
fish oil as a source of EPA and DHA in the human
diet.
Effectiveness of transgenic Camelina sativa
oil compared to fish oil on EPA and DHA
uptake and incorporation into blood lipids
A recent study funded by the Biotechnology and Bio-
logical Sciences Research Council UK has conducted
the first evaluation in humans of the effectiveness as a
source of EPA and DHA of an oil from a transgenic
plant that produces EPA and DHA compared to fish
oil (West et al. 2019, 2020a,b). The study tested the
seed oil from transgenic C. sativa that contained 11%
EPA and 9% DHA (Ruiz-Lopez et al. 2014), which
had been shown to be effective in increasing EPA and
DHA concentrations in farmed salmon and sea bream
(Betancor et al. 2016, 2017). The triacylglycerol
(TAG) molecular species composition of the transgenic
oil differed substantially from the commercially pre-
pared blended fish oil which was used as a comparator
(West et al. 2020b). In order to test whether such dif-
ferences in the composition of the oils affected absorp-
tion and appearance in blood, the EPA and DHA
incorporation into plasma lipids was assessed over an
8-hour postprandial period. Participants were healthy
Figure 1 Proportions of eicosapentaenoic acid (EPA) and docosahex-
aenoic acid (DHA) in fish oil and in oils from transgenic (GM) plants that
were engineered to synthesise EPA and DHA. Values from Tocher et al.
(2019) and West et al. (2020a).
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adults with mean ( standard error of the mean) ages
25  1 years (both younger men and women),
57  1 years (older women) and 60  2 years (older
men). The study had a double-blinded, cross-over
design in which participants consumed a standardised
breakfast that included 450 mg EPA plus DHA, which
reflects the intake of EPA plus DHA recommended by
the UK government (SACN 2004), provided by either
blended fish oil or transgenic C. sativa oil, and incor-
poration into blood lipids was then followed over
8 hours (West et al. 2019). There were no significant
differences in the incremental area under the time ver-
sus concentration curve between the test oils in the
incorporation of EPA and DHA into plasma TAG,
phosphatidylcholine (PC) or non-esterified fatty acids
(NEFA) during the postprandial period (Fig. 2). There
was no statistically significant effect of sex on the
incorporation of EPA and DHA into these lipid pools.
Incorporation of EPA and DHA into plasma TAG, PC
and NEFA was approximately 40–60% greater in
older subjects compared to the younger participants,
although there were no statistically significant interac-
tion effects of age, sex and test oil.
The postprandial period is associated with
increased concentrations in blood of specific pro-in-
flammatory cytokines (Burdge & Calder 2005b). The
findings of West et al. (2019) showed no significant
difference between test oils in the postprandial
changes in the concentrations of TNFa, interleukin
(IL)-6 or IL-10 and the soluble intercellular adhesion
molecule-1 (West et al. 2019). Since the anti-inflam-
matory effect of EPA and DHA is well established
(Miles & Calder 2012), one possible implication of
this finding is that the transgenic C. sativa oil may
suppress inflammation in a similar extent and manner
to fish oil. Fish oil has been suggested to potentially
have utility in the management of patients with sev-
ere, acute inflammatory diseases such as sepsis (Hall
et al. 2016) and COVID-19 (Bistrian 2020; Torrinhas
et al. 2020). Hence, it is possible that transgenic C.
sativa oil may also have therapeutic value in such
patients.
In order to test whether this transgenic C. sativa oil
was as effective as fish oil in increasing plasma lipid
EPA and DHA concentrations over the longer term,
Figure 2 Postprandial incorporation of eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) into plasma lipids when consumed as blended
fish oil or transgenic C. sativa oil. Values are mean  SEM incremental area
under the curve (iAUC) concentrations of EPA plus DHA over 8 hours in
plasma. YF, young females; YM, young males; OF, older females; OM, older
males. n = 10 participants per group. Data are from West et al. (2019).
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the same group carried out an 8-week, single-blinded,
cross-over, dietary supplementation trial in a com-
bined group of healthy men and women aged between
20 and 74 years (median 53 years; West et al. 2020a).
Participants consumed 450 mg/day EPA plus DHA
provided as either transgenic C. sativa oil or blended
fish oil using oral dosing syringes for 8 weeks, fol-
lowed by 6 weeks washout before consuming the
other oil for 8 weeks. Median compliance was greater
than 95% for both test oils. Consuming either test oil
increased EPA and DHA concentrations in plasma
TAG, PC and NEFA, and there were no significant
differences between test oils in the magnitude of the
increment in plasma EPA and DHA concentrations
(Fig. 3). The concentration of TAG in a combined
VLDL + chylomicron fraction was reduced signifi-
cantly and to a similar extent after consuming fish oil
(15%) or transgenic C. sativa oil (11.7%),
although there was no significant effect of either oil
on total plasma TAG concentration. Moreover, con-
suming either oil increased the omega-3 index (Harris
& Von Schacky 2004) by approximately 0.6 % points
(West et al. 2020a). However, the study was not pow-
ered to detect changes in these secondary outcomes
and so the findings should be regarded as indicative of
the potential for health benefits from consuming the
transgenic C. sativa oil rather than as evidence of effi-
cacy.
The blended fish oil and the transgenic C. sativa oil
were well tolerated in both trials with no adverse
events that could be attributed to consuming either
test oil. However, one participant withdrew from the
dietary supplementation trial because they found the
fish oil supplement unpalatable.
Figure 3 Change from baseline of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) concentrations in plasma lipids when consumed as blended
fish oil or transgenic C. sativa oil. Values are mean  SEM increments in EPA and DHA concentrations after dietary supplementation with these test oils for
8 weeks. n = 31 participants. Data are from West et al. (2020a).
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Conclusions and future perspectives
The recent studies that tested the efficacy of transgenic
C. sativa oil as a source of EPA and DHA for human
consumption indicate that this oil is an effective alter-
native to fish oil. One important implication of these
findings is that this oil could potentially overcome the
present challenges to achieving adequate intakes of
EPA and DHA in the general population; namely per-
ceived unpalatability and incompatibility with dietary
choices that exclude food groups that contain EPA
and DHA including meat, oily fish and dairy products.
Moreover, the production of transgenic C. sativa can
potentially be scaled to meet demands (Han et al.
2020) in a manner that could not be readily achieved
by costly fermentation of algae or wild capture of oily
fish, hence reducing the negative impact on the marine
environment of producing EPA and DHA for direct
human consumption and for aquaculture.
Field trials have demonstrated the stability and
robustness of the transgenic trait of C. sativa that pro-
duces EPA and DHA (Han et al. 2020), thus further
supporting the sustainability and scalability of this
crop which, therefore, represents a novel opportunity
for agricultural innovation and commercialisation.
However, in some countries, most notably the EU, leg-
islation impeding the commercial cultivation of trans-
genic plants for human consumption remains a barrier
to realisation of such benefits. With the UK’s depar-
ture from the EU, it will be interesting to see whether
new opportunities for the production of such trans-
genic crops emerge, although cultivation in parts of
the world with fewer legislative restraints (such as
North and South America) is a more immediately tan-
gible opportunity. One key development objective is
to formulate the means of incorporating the seed oil
from transgenic C. sativa that produces EPA and
DHA into the human food chain in a manner which is
cost-effective, preserves the biologically important
PUFA, allows wide consumption and is compatible
with most dietary choices.
Overall, transgenic C. sativa that produces EPA and
DHA could potentially make a significant contribution
to facilitating nutrient security with respect to n-3
PUFA while reducing the burden on the marine envi-
ronment of sourcing these fatty acids for human con-
sumption.
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